Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083824 · ClinicalTrials.gov registry record · Phase 2
Estrogen, HDL, and Coronary Heart Disease in Women
A Phase 2 study of Cardiovascular Diseases and Heart Diseases, sponsored by Tufts University.
- Completed
- Registry status
- Phase 2
- Development phase
- 309
- Enrollment target
- 1
- Study location
NCT00083824: Completed Phase 2 study of Cardiovascular Diseases and Heart Diseases, sponsored by Tufts University.
NCT00083824 is a Phase 2 study of Cardiovascular Diseases and Heart Diseases that has completed, run by Tufts University. The registered enrollment target is 309 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083824, a Phase 2 study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 309 participants
- Enrollment target
- 1
- Study location
Study Summary
To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.
Primary Outcome
To assess the effect of hormonal replacement therapy on HDL subpopulation profile and HDL composition in postmenopausal women with established CHD
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Medroxyprogesterone 17-Acetate
- DRUG Estrogens, Conjugated (USP)
Study Locations (1)
Massachusetts
- HNRCA at Tufts University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00083824 record still lists
NCT00083824 is an interventional study that assigns participants to a tested intervention. The registered 309 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00083824 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00083824 about?
NCT00083824 is a clinical study titled "Estrogen, HDL, and Coronary Heart Disease in Women". To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.
What is the current status of trial NCT00083824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2004-03. Estimated completion is 2007-02.
What conditions does trial NCT00083824 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Coronary Disease, Coronary Arteriosclerosis.
What interventions are being tested in trial NCT00083824?
The interventions under investigation include: Placebo (DRUG), Medroxyprogesterone 17-Acetate (DRUG), Estrogens, Conjugated (USP) (DRUG).
Who is sponsoring clinical trial NCT00083824?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083824 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00083824's enrollment target sits among peer trials
309 120th of 300 higher than 181 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03011684 · 309 participants · Phase 3
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- NCT06915233 · 309 participants · Phase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia